Janus Henderson Group’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
Janus Henderson Group's CTNM Position: Q3 2026 in Review
Janus Henderson Group opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 1,723,312 shares worth $23.1M. The stake represents 0.01% of the portfolio and ranks #604 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in CTNM as recently as Q1 2026.
Janus Henderson Group first reported a position in CTNM in Q4 2024 and has held it in 5 quarters since. The position peaked at $35.6M in Q1 2026. 110 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- Janus Henderson Group held 1,723,312 shares of Contineum Therapeutics worth $23.1M as of Q3 2026.
- Contineum Therapeutics was a new Janus Henderson Group position in Q3 2026.
- Contineum Therapeutics made up 0.01% of Janus Henderson Group's portfolio in Q3 2026, its #604 holding.
- Janus Henderson Group first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 5 quarters since.
- Janus Henderson Group's Contineum Therapeutics position peaked at $35.6M in Q1 2026.
- 110 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.